Andermatt Biocontrol AG – Trademark Portfolio
Entity Type: 98
Andermatt Biocontrol AG holds 35 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 27 filings in this category. The portfolio also extends into Class 1 (Chemicals) across 4 Nice Classification classes. Currently, 6 trademarks are registered. Notable registered marks include AMYBAC, TUTAVIR, LITTOVIR, ANDERMATT, and DROSALURE.
Showing of trademarks Trademarks
Trademark Classifications
Andermatt Biocontrol AG's trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Common metals and their alloys; metal building materials; transportable buildings of metal
Frequently Asked Questions
How many trademarks does Andermatt Biocontrol AG have?
Andermatt Biocontrol AG has 35 U.S. trademarks filed with the USPTO. Of these, 6 registered, 1 abandoned, 2 cancelled.
What trademark classes does Andermatt Biocontrol AG file in?
Andermatt Biocontrol AG files trademarks across 4 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 1 (Chemicals), Class 21 (Housewares), Class 6 (Metal Goods). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Andermatt Biocontrol AG's most well-known trademarks?
Andermatt Biocontrol AG's registered trademark portfolio includes well-known marks such as AMYBAC, TUTAVIR, LITTOVIR, ANDERMATT, and DROSALURE. These are among 6 currently registered trademarks in the portfolio.
What is Andermatt Biocontrol AG's trademark registration success rate?
Andermatt Biocontrol AG has a 67% trademark registration rate, with 6 out of 9 resolved applications resulting in successful registration. Currently, 0 applications are pending review.